Worldclass sites, 17 plants in all, across three continents enables us to compete with a tight handle on cost and time to market across the geographies we are present in, and compete with interesting products that are difficult to replicate. During the course of the year we completed projects in streamlining, upgradation and expansion across several of our plants.

API Manufacturing: Our expertise in API manufacturing enables us to work with innovative companies as a sourcing partner & benefit from the advantages of integration with a tight handle on cost & delivery. Our API filings strengthen our presence worldwide & specially in the US where it enables us to source API for ANDA opportunities. In addition to sourcing for very large products (like pantoprazole) we expect to use the dossier development & filing capability for anticancers, steroids, hormones as well.

Alkaloida, our Hungarian manufacturing site that we’d acquired in 2005, is a facility that can make API of controlled substances like morphine, codeine and their derivatives from the initial stages. Over time, we intend to integrate the sourcing of API from this plant to our controlled substance formulations factory in Cranbury, US. In readiness for filing, extensive engineering changes were carried out over the previous year, GMP standards enforced & utilities upgraded significantly.

At our Panoli API plant which we commissioned in 1995 & expanded several times over the course of the last decade, we doubled our plant size with an expansion. The new site houses plants for anticancer and steroid API manufacture, a large warehouse, utility block, tank farm & solvent storage.

Plant 6 is large multiproduct API facility for regulated markets such as the US, plant 7 is dedicated for making sex hormones, and includes a sterile facility. Since these hormones are effective in minute quantities, the plant has stringent controls and the highest checks on utilities.

At Ahmednagar, an oncology plant over four floors with 18 reactors and 8.21 kilolitre capacity with separate air handling systems and restricted material movement was commissioned. We expect to scale up complex anticancers such as oxaliplatin, capcetabine, gemicitabine at this plant, which has been built to USFDA specifications.

At our Karkhadi plant, a plant to manufacture formulations has been made operational and the area for non-sterile formulations such as liquids & tablets has since received USFDA approval for cefuroxime axetil. We expect our API business to continue to feed our dosage form business, and strengthen our ability to compete internationally.

Formulation Manufaturing >>